Oncology Industry Veteran to Lead International Expansion and Strategic Partnerships for the elive™ Platform
MADISON, Wis., July 16, 2026 – Elephas Biosciences Corporation, a private company that has developed an innovative live tissue platform for immunotherapy response prediction, welcomes Geoff Muckle as Executive Vice President, International. In this role, Geoff will drive Elephas’ commercialization strategy outside of North America, building the partnerships and market strategies needed to support the company’s long-term global growth.
With nearly three decades in oncology and precision medicine commercialization, Geoff has helped organizations build international partnerships, navigate regulatory and reimbursement pathways, and scale operations to meet growing demand. At Elephas, he will oversee the company’s international market strategy and drive adoption of the elive platform among priority global partners.
As Elephas expands access to the elive platform, Geoff will play a key role in bringing the technology to biopharmaceutical companies, researchers, and oncology organizations working to improve outcomes for cancer patients. The platform provides real-time functional response prediction, helping to address a persistent challenge in immunotherapy, where only one in five patients responds to treatment.
Before joining Elephas, Geoff founded LINK Genes Ltd, an AI-driven oncology company, and LINK Medical Solutions Ltd, an international oncology distribution and advisory business. He previously served as CEO of Onconox Inc. and Imagen Therapeutics Ltd., leading commercialization efforts with partners including AstraZeneca, AbbVie and Bristol Myers Squibb. He also held strategic roles at both Champions Oncology and Roche.
“Geoff’s track record building international partnerships and scaling oncology technologies makes him the right leader as we begin to commercialize and build our team in these regions,” said Maneesh Arora, Elephas founder and CEO. “We are confident he will accelerate the awareness and reach of elive around the world.”
“I’ve built my career bringing new technologies to the researchers and clinicians who can put them to work for patients,” said Geoff Muckle, Elephas Executive Vice President, International Commercial Strategy. “What excites me about elive is the true unmet need, and I look forward to having a direct impact bringing elive to the world.”
About Elephas Biosciences
Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite a significant increase in the number of available immunotherapies, only 1 in 5 patients receiving immunotherapy obtain a response and many who may respond are not eligible for therapy due to lack of accurate predictive biomarkers. With the mission to tackle this growing dilemma, Elephas has developed an ex-vivo platform to assess how live biopsies respond to immunotherapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the elive platform enables a real-time characterization of immune response. To learn more, visit www.elephas.com and follow us on LinkedIn.
Media Contact
John Fitzpatrick
Investor Contact
Ji-Yon Yi